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The delivery of drugs is a topic of intense research activity in both academia and industry 28 
with potential for positive economic, health, and societal impacts. The selection of the 29 
appropriate formulation (carrier and drug) with optimal delivery is a challenge investigated 30 
by researchers in academia and industry, in which millions of dollars are invested annually. 31 
Experiments involving different carriers and determination of their capacity for drug 32 
loading is very time consuming, and therefore expensive; consequently, approaches that 33 
employ computational/theoretical chemistry to speed have the potential to make hugely 34 
beneficial economic, environmental and health impacts through savings in costs associated 35 
with chemicals (and their safe disposal) and time. Here we report the use of computational 36 
tools (data mining of available literature, principal component analysis, hierarchical 37 
clustering analysis, partial least squares regression, autocovariance calculations, molecular 38 
dynamic simulations and molecular docking) to successfully predict drug loading into 39 
model drug delivery systems (gelatin nanospheres). We believe that this methodology has 40 
the potential to lead to significant change in drug formulation studies across the world. 41 
 42 
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 52 
1. Introduction 53 
The global market for drug-delivery systems is a multibillion-dollar industry, demand 54 
for which is growing in both developed and emerging economies (in part, driven by aging 55 
societies and rapid urbanization) 1-9. Drug-delivery systems deliver drugs at rates controlled 56 
by specific features of the systems, particularly their chemical composition (e.g., 57 
inorganic/organic components, molecular weights of their constituents, crosslinking density 58 
of polymers, etc.) 10-12. 59 
The selection of the appropriate system (carrier and drug) to obtain optimal delivery is a 60 
challenge investigated by researchers in academia and industry, in which millions of dollars 61 
are invested annually 13. Experiments involving different carriers and determination of their 62 
capacity for drug loading is very time consuming, and therefore expensive. Consequently, 63 
approaches that exploit multivariate statistical methods, molecular simulations, docking 64 
methods, and mining the data in the literature 14-19, have the potential to make hugely 65 
beneficial economic, environmental and health impacts through savings in costs associated 66 
with chemicals (and their safe disposal) and time. 67 
Computational/theoretical chemists/biochemists, biomedical/chemical engineers and 68 
pharmacists have developed a variety of methodologies that can be applied to understand 69 
drug formulations. Principal component analysis (PCA) and hierarchical clustering analysis 70 
(HCA) are considered exploratory data analysis and unsupervised machine learning 71 
methods, where these techniques extract patterns from the independent factors (x-variables) 72 
only and irrelevant to the y-outcomes. Partial least squares (PLS) is a supervised pattern 73 
recognition method correlating the inputs with outputs and subsequently leads to the 74 
generation of a model 20. This data mining approach (through a retrospective analysis) 75 
combined with computer-aided analysis and simulation extracts knowledge from complex 76 
variables and responses obtained from historical records. The significant advantage of this 77 
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approach is the possibility of uncovering interactions and linear relationships that might not 78 
be easily detectable with conventional experimental designs 21. Although not yet fully 79 
explored in drug formulation/delivery, multivariate statistical methods such as PCA and 80 
agglomerative HCA were previously used to develop drug delivery formulations. For 81 
example, PCA was utilized to generate a quantitative composition-permeability relationship 82 
for microemulsion formulations used to deliver testosterone transdermally, with a linear 83 
relationship between the lower-dimensionality data generated from the main principal 84 
component and the permeability coefficients of the different formulations 22. PCA and HCA 85 
were used to extract stable SMEDDS (Self Microemulsifying Drug Delivery Systems) and 86 
SNEDDS (Self Nanoemulsifying Drug Delivery Systems) formulations of Lovastatin and 87 
Glibenclamide, respectively 23,24; and PCA and PLS analysis were used to assess the 88 
qualitative and quantitative effects of different variables such as lipid/surfactant type and 89 
their concentrations on parameters related to storage stability 25. Furthermore, PLS was 90 
successfully employed to predict the sizes and polydispersity index (PDI) for lipid 91 
nanocapsules based on the quantitative mixture composition 26.  92 
Here we extend these exciting studies by combining PCA, HCA and PLS with molecular 93 
dynamics and docking analysis 27 to give valuable insight into drug loading in a polymer 94 
matrix. As a model polymer matrix we use protein-based nanoparticulate drug delivery 95 
systems (i.e. nanospheres composed of collagen-derived gelatin). Gelatin is an abundant and 96 
inexpensive protein 28, which is amphiphilic in nature due to its amino acid contents (ca. 12% 97 
anionic glutamic and aspartic acid; ca. 13% cationic lysine and arginine amino acids, and ca. 98 
11% hydrophobic leucine, isoleucine, methionine and valine) 29, and gelatin-based matrices 99 
can in principle be used to deliver both small molecules and macromolecules 30-36. In this 100 
study we focus on a selection of low molecular weight drugs used in the clinic as depicted in 101 
Figure 1. 102 
 103 




Figure 1. The chemical structures of the substances studied herein: A) Acyclovir, 106 
B) Cryptolepine, C) Amphotericin B, D) Doxorubicin, E) 5-Fluorouracil (5FU), F) 107 
Isoniazid, G) Resveratrol, H) Paclitaxel, I) Indomethacin and J) Curcumin. 108 
 109 
2. Materials and Methods  110 
2.1. Data set 111 
The data set contained 4 input variables (descriptors) and one output response (mass of 112 
drug loaded per 100 mg gelatin nanospheres determined experimentally) for different drugs. 113 
Data mining was performed through different databases such as: Pubmed and Web of 114 
Science® to obtain the output response for ten drugs: Acyclovir 37, Amphotericin B 38, 115 
Cryptolepine 39, Doxorubicin 40, 5 Fluorouracil (5FU) 41, Isoniazid 42, Resveratrol 43, 116 
curcumin 44, paclitaxel 45 and indomethacin 46. 117 
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 118 
2.2. Calculation of molecular descriptors 119 
The drugs were analyzed using Bioclipse® version 2.6 (Bioclipse project, Uppsala 120 
University, Sweden) [39]. The four descriptors chosen were constitutional (molecular 121 
weight), electronic (number of hydrogen bond donors and number of hydrogen bond 122 
acceptors) and physico-chemical (xLog P). 123 
 124 
2.3. Hierarchical clustering analysis (HCA). 125 
The molecular descriptors generated using Bioclipse® version 2.6 were subjected to 126 
Hierarchical Clustering Analysis using JMP® 7.0 (SAS, Cary, NC, USA). Ward’s minimum 127 
variance method was adopted to join the clusters and generate a dendrogram. Ward’s method 128 
is considered an agglomerative hierarchical technique where the merging in the dendrogram 129 
starts at the final clusters (leaves) and merging occurs stepwise until it reaches the trunk. 130 
Ward's minimum variance criterion minimizes the total within-cluster variance. At each step, 131 
the pair of clusters possessing minimum between-cluster distance is merged (i.e. the pair of 132 
clusters that leads to the minimum increase in the total within-cluster variance after merging 133 
is selected) 47 . 134 
 135 
2.4. Principal component analysis (PCA). 136 
PCA was used to extract patterns using an exploratory data analysis method that deals 137 
with the variances in sample observations. PCA was performed using JMP® 7.0. Four 138 
principal components were calculated by taking a linear combination of an eigenvector of the 139 
correlation matrix built up from standardized original variables. The dimensionality of the 140 
data was reduced by extracting two main principal components possessing the two highest 141 
Eigen values and plotting the data with respect to these two new orthogonal axes. 142 
 143 
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2.5. Partial least squares analysis (PLS) for model generation and validation of the model. 144 
PLS was used to study correlations between the molecular descriptors and the output 145 
response. PLS was performed using JMP® 7.0 using 4 latent vectors. The PLS generated 146 
model was validated by checking the differences between the mean actual and predicted 147 
response values using t-test statistical analysis at P < 0.05 using GraphPad Prism® v.5.0 148 
(GraphPad software Inc., San Diego, CA, USA) and by performing a k-fold (5-folds) 149 
cross-validation (leave-two-out) to check the predictability of the model and its ability to 150 




  153 
Where PRESS represents the predicted residual error sum of squares while ISS stands for the 154 
total initial sum of squares. Moreover, a predicted versus actual correlation was obtained. 155 
 156 
2.6. Molecular dynamics simulations (MDS) of the gelatin matrix. 157 
Molecular dynamics simulations (MDS) were carried-out using the GROMACS 48 v. 158 
4.6.5 freeware (http://www.gromacs.org/). To prepare the gelatin system, 48 peptide 159 
molecules were constructed, with 18 amino acids in each molecule. The primary sequence of 160 
the peptides was AGPRGQ(Hyp)GPAGPDGQ(Hyp)GP. Six hypothetical probe molecules 161 
(with calculated molecular weight of 767.13) were added at random positions to the system. 162 
The force field parameters were obtained from CgenFF 49 (https://cgenff.paramchem.org/). 163 
The system was energy minimized by the steepest descent method. Molecular dynamics was 164 
subsequently carried-out, with a time step of 2 fs, full periodic boundary conditions, and a 165 
cut-off distance of 1.2 nm for Van der Waal’s and electrostatic interactions 50. PME was 166 
chosen to handle long-range electrostatic interactions. All bonds were constrained by the 167 
LINCS algorithm. The MDS were carried-out for 3 ns, at 373K and 1 bar using a v-rescale 168 
thermostat and a Berendsen barostat respectively 51. 169 
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 170 
2.7. Drug docking in simulated gelatin nanospheres. 171 
The chemical structures of the studied drugs were drawn using ChemDraw® Ultra 172 
version 10 (Cambridgesoft, Waltham, MA, USA). The corresponding ‘.mol2’ files needed 173 
for docking experiments were obtained using Chem3D® Ultra version 10 (Cambridgesoft, 174 
Waltham, MA, USA) after energy minimization using the MM2 force field of the same 175 
program. Docking analysis was generated by Argus Lab version 4.0.1. (Mark Thompson and 176 
Planaria Software LLC, Seattle, WA, USA). The hypothetical probe molecules were utilized 177 
to construct corresponding binding sites on the carrier (gelatin-probe), the AScore was 178 
utilized for calculating the scoring function. The size of the display box in the x, y and z 179 
dimensions were 15 x 15 x15 Å as these dimensions were suitable to the size of the docked 180 
molecules and ensured a central position for them inside the gelatin matrix. Additionally, the 181 
genetic algorithm was used as the docking engine with 150 maximum poses. The type of 182 
calculation and ligand (as chosen using the software options) were Dock and Flexible, 183 
respectively; and the binding energies (ΔG, kcal/mole) reflecting the docking efficiencies 184 
were calculated. 185 
 186 
3. Results 187 
Table 1 reports the molecular descriptors (number of hydrogen bond donors, number of 188 
hydrogen bond acceptors, xLogP and molecular weight) for the investigated drugs. The 189 
dendrogram classifying these drugs according to HCA using Ward’s minimum variance 190 
method (an agglomerative type of analysis) is displayed in Figure 2. Isoniazid and 5FU were 191 
clustered together according to their 4 descriptors, Resveratrol and Cryptolepine clustered 192 
together, whereas Doxorubicin, Acyclovir and Amphotericin B constituted separate clusters. 193 
Importantly, the loading pattern followed this classification (see Table 1) where 5FU and 194 
Isoniazid scored the highest loading masses followed by Acyclovir which is closest to the 195 
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aforementioned drugs in the dendrogram. Cryptolepine and Reseveratrol were very close, 196 
with Doxorubicin near to them. Amphotericin B had the lowest mass loaded into the 197 
nanospheres which was clear from its separate branch (furthest distance) in the dendrogram. 198 
Table 1. The descriptors of the drugs, amounts of loaded drug, and the obtained 199 






















Acyclovir -1.650 3 8 225.21 8.74 -3.94 
Amphotericin 
B 
2.068 12 18 923.49 1.16 144.4 
Cryptolepine 2.180 0 2 233.30 2.00 -3.81 
Doxorubicin -1.900 6 9 543.52 2.10 58.29 
5-Fluorouracil -0.760 2 4 130.00 25.07 -4.19 
Isoniazid -0.683 3 4 137.14 22.00 -4.16 
Resveratrol 2.050 3 3 228.24 1.96 -3.74 
Curcumin 1.95 2 6 368.13 3.50 -2.59 
Paclitaxel 6.15 4 14 853.33 0.52 173.5 
Indomethacin 3.78 1 4 338.14 1.91 -1.99 
 201 
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 202 
Figure 2. Hierarchical Clustering Analysis (HCA) of the investigated drugs with 203 
respect to 4 constitutional, electronic and physico-chemical descriptors: number of 204 
hydrogen bond donors, number of hydrogen bond acceptors, xLogP and molecular 205 
weight. 206 
 207 
A score plot of the drugs with respect to their descriptors after projecting the data into 208 
two main principal components is displayed in Figure 3, where principal component 1 and 209 
principal component 2 reflect 69.72% and 26.95 % of the data variation, respectively 210 
(corresponding to 96.68 % of total variance, Figure 3, top right panel) and 5FU and Isoniazid 211 
are clustered together with Acyclovir having the nearest score, and Amphotericin B the 212 
furthest score. Figure 4 depicts the loading plots of the two main principal components. It is 213 
obvious that principal component 1 is mainly composed of the descriptors; the molecular 214 
weight, the number of the H-bond donors and the number of the number of H-bond acceptors 215 
while principal component 2 mainly depends on the remaining descriptor; xLogP. These 216 
results confirm the presentation of the 4 investigated variables in the two generated principal 217 
components. 218 




Figure 3. Principal Component Analysis (PCA) score plot of the investigated drugs 221 
with respect to 4 constitutional, electronic and physico-chemical descriptors: 222 
number of hydrogen bond donors, number of hydrogen bond acceptors, xLogP and 223 
molecular weight, displaying only two main combined components. The upper 224 
panel depicts the scree plot revealing the percentage variation of each extracted 225 
component (combined from the four descriptors). 226 
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 227 
Figure 4. Principal Component Analysis (PCA) loading plot of the two main principal 228 
components. 229 
 230 
The relationship between the obtained combined x-scores (combining the contribution 231 
from the 4 x-variables viz. descriptors) and y-scores is displayed in Figure 5, and the scree 232 
plot (Figure 5, bottom right) depicts the contribution of each individual latent factor to the 233 
combined x-scores with the first two factors accounting for 96.64% of the obtained scores. 234 
 235 
 236 
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Figure 5. Partial Least Squares Regression Analysis (PLS) of the investigated drugs 237 
with 4 constitutional, electronic and physico-chemical descriptors: number of 238 
hydrogen bond donors, number of hydrogen bond acceptors, xLogP and molecular 239 
weight as the x-factors and the mass of loaded drug per 100 mg gelatin nanoparticles 240 
as the y-factor. The lower panel depicts the contribution of each latent x-factor 241 
(combined factor) to the x-scores representing the combined x-dimension. 242 
 243 
It is noteworthy that the generated x- and y- scores represent the distances of the points 244 
in space of all the dimensions to the main vector summarizing the final dimension (in the 245 
current case there is a principal component or vector for the x-dimension comprising all the 246 
descriptors, and another for the y-dimension representing the loaded mass). Therefore, the 247 
aforementioned scores can be negative numbers. Consequently, a generated model was 248 
developed where: 249 
Y (mass of drug loaded per 100 mg of gelatin nanoparticles) = 13.175 + 0.115 × 
xLogP + 0.001 × number of hydrogen bond donors + 2.346 × number of 
hydrogen acceptors – 0.059 × molecular weight. (1) 
The values and the signs of the coefficients of the x-factors in the equation were 250 
indicative of the importance of increasing the number H- bond acceptors in the drugs 251 
chemical structure in the presence of a balanced xlogP and low molecular weight to increase 252 
the loading of the drug. The model was validated by performing a t-test statistical analysis 253 
between the actual experimental results for drug loading and the predicted drug loading using 254 
the model where no significant difference was obtained between the means at P < 0.05. The 255 
calculated Q2 or the predicted r-squared after 5-folds cross-validation scored a value of 0.721 256 
(a highly acceptable value) 52. Figure 6 further demonstrates the predicted versus actual 257 
relationship where it is observed that most of the points are scattered around the 45⁰ line. 258 
Proximity of the points to this line usually indicates the favorable similarity of the results. 259 
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Accordingly, the developed model can be exploited in predicting the loaded mass of any new 260 
physically loaded or entrapped investigated drug molecule in a gelatin matrix after projecting 261 
its structure to the aforementioned four descriptors (Table 1). 262 
 263 
Figure 6. Predicted versus actual drug loading in gelatin nanospheres. 264 
 265 
4. Discussion 266 
In the HCA utilized and studied method (Ward’s method), the distance between two 267 
clusters is the ANOVA sum of squares between the two clusters added up over all the 268 
variables. At each generation, the within-cluster sum of squares is minimized over all 269 
partitions obtainable by merging two clusters from the previous generation. The sums of 270 
squares are usually easily interpreted when they are divided by the total sum of squares to 271 
give the proportions of variance (squared semi-partial correlations). Ward's method works 272 
under the assumptions of spherical covariance matrices and the condition of equal sampling 273 
probabilities. Distances between clusters in Ward's method are calculated according to the 274 
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squared Euclidean distance. It is considered very useful in joining clusters with a small 275 
number of observations and it is very accurate though sensitive to outliers 53. 276 
PCA was used to confirm the hierarchical clustering analysis results. This type of 277 
multivariate analysis deals with the x-factors (descriptors) to reduce their dimensionality by 278 
projecting the data into new orthogonal axes that display the directions (vectors) of the 279 
highest variation. These results confirmed the HCA results and correlate the x-factors (drug 280 
descriptors) with the y-outputs (mass of drug loaded per 100 mg of gelatin) where clustered 281 
points (Especially in the same quadrants) represents high similarity between them regarding 282 
their projected descriptors 54. 283 
Accordingly, a supervised learning tool (PLS) was used to generate an accurate and 284 
sensitive model that would correlate the x-factors with the y-outputs quantitatively.  The 285 
techniques implemented in the PLS platform work by extracting successive linear 286 
combinations of the predictors, called factors (also called components or latent vectors), 287 
which optimally address the combined goals of explaining both response and predictor 288 
variation. In particular, the method of PLS balances the two objectives and maximizes their 289 
correlation 55. 290 
The obtained results can be explained by the fact that gelatin is a protein carrier with a 291 
relatively balanced hydrophilic/hydrophobic character displaying several hydrogen bond 292 
donor and acceptor groups with a repetitive sequence of amino acids 293 
-Ala-Gly-Pro-Arg-Gly-Glu-4Hyp-Gly-Pro- along its backbone 56. This structure can be 294 
transformed to some numerical values that are generated of each amino acid. Among which 295 
are the highly condensed variables “z-scale descriptors” 57 that are derived from a PCA 296 
analysis of several experimental and physicochemical properties of the 20 natural amino 297 
acids; z1, z2, and z3 and which represent the amino acids hydrophobicity, steric properties, 298 
and polarity, respectively. Additionally, they are useful in QSAR analysis of peptides where 299 
they have proven effective in predicting different physiological activities 58-60. Herein, we 300 
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used an extended scale (including 67 more artificial and derivatized amino acids) 61 due to the 301 
presence of 4-hydroxyproline in the gelatin structure. 302 
In this study, we expand the use of the first descriptor (z1) to predict the drug loading 303 
properties of nanoparticles. The first scale (z1) was chosen as it represents a lipophilicity 304 
scale that encompasses several variables (amino acid descriptors) such as: the thin layer 305 
chromatography (TLC) variables, log P, nonpolar surface area (Snp) and polar surface area 306 
(Spol) in combination with the number of proton accepting electrons in the side chain 307 
(HACCR) 62. In this scale, a large negative value of z1 corresponds to a lipophilic amino acid, 308 
while a large positive z1 value corresponds to a polar, hydrophilic amino acid. Therefore, the 309 
gelatin typical structure amino acids (-Ala-Gly-Pro-Arg-Gly-Glu-4Hyp-Gly-Pro-) can be 310 
represented by their z1 values as follows: (0.24), (2.05), (-1.66), (3.52), (2.05), (3.11), 311 
(-0.24), (2.05) and (-1.66). Furthermore, an overall topological description of the repetitive 312 
sequence was accounted for by encoding the z1 descriptors of each amino acid into one auto 313 
covariance variable [49] that was first introduced by Wold et al. 63. The auto covariance value 314 





where AC represents autocovariances of the same property (z-scale); i = 1, 2, 3,...; N is the 316 
number of amino acids; lag = 1, 2, 3, ... L (where L is the maximum lag which is the longest 317 
sequence used and V is the scale value). 318 
Therefore, the AC value for the gelatin typical structure sequence was calculated with 319 
lag 1 scoring a value approaching zero (0.028) indicating a balanced 320 
hydrophobicity/hydrophilicity structure. In light of the above, the high loading of 5FU and 321 
Isoniazid can be ascribed to their amphiphilic nature with LogP values approaching 0, and to 322 
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the presence of several hydrogen bond donors and acceptors groups relative to their low 323 
molecular weight that is favorable in both diffusion through and entrapment in a protein 324 
matrix like that of gelatin nanospheres. Since there was a recorded deviation between the 325 
actual and the predicted values regarding Isoniazid and 5FU (may be attributed to their small 326 
molecular weight that helps their non-stoichometric physical entrapment in the gelatin 327 
matrix, therefore, the results were further confirmed by molecular dynamics and docking 328 
experiments, where the drugs were docked on the gelatin matrix simulated structure. Figure 329 
7 shows the molecular simulation of the gelatin nanosphere matrix. Interestingly, the best 330 
binding energy values ΔG (- 4.19 and -4.16 kcal/mol) corresponded to the highest loaded 331 
drugs 5FU and Isoniazid, respectively, followed by Acyclovir (see Figure 8). In the same 332 
context, Amphotericin B scored a highly positive ΔG value which explains its low loading 333 
values. The confirmation of the docking results with their experimental counterparts can be 334 
attributed to the inclusive scoring function of the Arguslab® software. This scoring function 335 
is based on the XScore calculated according to the following equation 64: 336 
ΔGbind = ΔGvdw + ΔGhydrophobic + ΔGH-bond + ΔGH-bond (chg) + ΔGdeformation + ΔG0 (3) 
where ΔGbind is the total calculated binding energy, ΔGvdw is the binding energy due to Van 337 
der Waal’s forces, ΔGhydrophobic is the binding energy due to hydrophobic forces, ΔGH-bond is 338 
the binding energy due to H-bonding, ΔGH-bond (chg) is the binding energy due to H-bonding 339 
due to charged molecules, ΔGdeformation is the energy due to rotational bonds and atoms 340 
involved in torsions (rotors) that were frozen due to binding, and finally, ΔG0 represents the 341 
regression-obtained binding energy. As can be inferred, the equation terms encompass nearly 342 
all the possible interactions that can occur between the drug and its carrier that may lead to 343 
drug entrapment which explains the high correlation obtained between the real experimental 344 
values and the docking results.  345 
An exponential model was generated correlating the actual experimental molar masses of the 346 
loaded drugs and their corresponding docking binding energies. This model was highly 347 
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fitting with an obtained r-squared value of 0.95. This relationship can highly estimate the 348 
molar masses of physically loaded drugs through docking the investigated molecule on the 349 
simulated gelatin matrix. The only limitation of the model was the number of the 350 
experimental studies that are involved in it (10 studies) which we recommend to increase in 351 
further similar studies. 352 
 353 
 354 
Figure 7. Molecular dynamics simulation of the gelatin nanosphere matrix. 355 
 356 
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 357 
Figure 8. Drug loading versus the obtained binding energies plot of the investigated 358 
drugs after docking on a simulated gelatin matrix built up using molecular dynamics 359 
simulation displaying an exponential relationship. 360 
 361 
5. Conclusions 362 
The current study introduces new approaches of interpreting and predicting drugs 363 
loading on protein carriers, such as gelatin nanospheres. These approaches comprise 364 
multivariate statistical methods such as: hierarchical clustering analysis, principal 365 
component analysis, partial least squares regression, molecular dynamics and docking. 366 
Moreover, the utilization of the amino acids z-scales descriptors represents a new and 367 
important asset in interpreting drug loading in protein-based carriers. We believe that this 368 
methodology has the potential to lead to significant change in drug formulation studies across 369 
the world. 370 
 371 
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